Treatment and Outcomes of Precocious Puberty: An Update
The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Precocious puberty is a common problem affecting up to 29 per 100,000 girls per year. The earliest identified neuroendocrine change in early puberty thus far is increased kisspeptin secretion from the arcuate nucleus and the anteroventral paraventricular nucleus of the hypothalamus. The regulation of kisspeptin secretion is not well understood, but neurokinin B and dynorphin provide autocrine regulation. The etiologies of precocious puberty may be subdivided into GnRH-dependent and GnRH-independent causes. GnRH-dependent precocious puberty, often called central precocious puberty (CPP), is usually treated with GnRH analogs. Newer developments in the treatment of CPP include expanded data on the safety and efficacy of the subdermal histrelin implant, which is useful for long-term treatment, although removal may be difficult in some cases. Preliminary data suggest that the implant may be left in place for up to 2 years without loss of biochemical suppression. In the last 2 years, more data have been published concerning extended-release leuprolide acetate injections that indicate that the 11.25-mg dose may not provide full biochemical suppression but may clinically suppress signs of puberty, including the accelerated growth velocity and advanced skeletal maturation seen in CPP. Treatment options for familial male-limited precocious puberty and McCune-Albright syndrome are expanding as well, although data are preliminary. Long-term outcome studies of CPP indicate overall good menstrual and reproductive function, but the prevalence of polycystic ovary syndrome may be higher than in the general population. Remarkably few studies have evaluated the behavioral and psychological outcomes of precocious puberty, in contrast to early normal maturation. Additional outcome studies of endocrine, metabolic, and psychological effects of CPP are clearly needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Enlarged testis corresponding with the pubertal stage suggests GDPP, while pre-pubertal testis indicates GIPP.”
From Congenital adrenal hyperplasia complicated by gonadotropin-dependent precocious puberty (2024) · cites this paper as [16]
In the citing paper
“Pubertal testis smaller than expected with pubic hair growth means apparent LH excess (hCG-secreting tumour or testotoxicosis) or GDPP superimposed on GIPP.16”
From Congenital adrenal hyperplasia complicated by gonadotropin-dependent precocious puberty (2024) · cites this paper as [16]
In the citing paper
“The most important pointer to the source of androgen production in a boy with precocious puberty is testicular volume.”
From Congenital adrenal hyperplasia complicated by gonadotropin-dependent precocious puberty (2024) · cites this paper as [16]
Citations
Cites
Variations in pattern of pubertal changes in girls
Marshall, W. A., & Tanner, J. M. (1969) · Archives of Disease in Childhood · doi:10.1136/adc.44.235.291 · Cited by 5,963 · cited 1×
“The degree of pubertal maturation is usually described using the Tanner stages of sexual maturation (4) (Table 1).”
MethodHerman-Giddens, M. E., Slora, E. J., Wasserman, R. C., Bourdony, C. J., Bhapkar, M. V., Koch, G. G., & Hasemeier, C. M. (1997) · PEDIATRICS · doi:10.1542/peds.99.4.505 · Cited by 1,709
Topaloglu, A. K., Reimann, F., Guclu, M., Yalin, A. S., Kotan, L. D., Porter, K. M., Serin, A., Mungan, N. O., Cook, J. R., Ozbek, M. N., et al. (2009) · Nature Genetics · doi:10.1038/ng.306 · Cited by 961 · cited 1×
“Although mutations of neurokinin b and dynorphin could theoretically cause early pubertal development, such mutations have not yet been identified (12).”
BackgroundConsensus Statement on the Use of Gonadotropin-Releasing Hormone Analogs in Children
Carel, J.-C., Eugster, E. A., Rogol, A., Ghizzoni, L., Palmert, M. R., & on behalf of the members of the ESPE-LWPES GnRH Analogs Consensus Conference Group (2009) · Pediatrics · doi:10.1542/peds.2008-1783 · Cited by 817 · cited 2×
“in those with CPP (30) than in those with normal puberty,”
BackgroundEarlier Onset of Puberty in Girls: Relation to Increased Body Mass Index and Race
Kaplowitz, P. B., Slora, E. J., Wasserman, R. C., Pedlow, S. E., & Herman-Giddens, M. E. (2001) · Pediatrics · doi:10.1542/peds.108.2.347 · Cited by 751
Wakabayashi, Y., Nakada, T., Murata, K., Ohkura, S., Mogi, K., Navarro, V. M., Clifton, D. K., Mori, Y., Tsukamura, H., Maeda, K.-I., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5848-09.2010 · Cited by 597 · cited 5×
“org J Clin Endocrinol Metab, June 2013, 98(6):2198–2207 doi: 10.”
BackgroundInfluentialA GPR54 -Activating Mutation in a Patient with Central Precocious Puberty
Teles, M. G., Bianco, S. D. C., Brito, V. N., Trarbach, E. B., Kuohung, W., Xu, S., Seminara, S. B., Mendonca, B. B., Kaiser, U. B., & Latronico, A. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa073443 · Cited by 572 · cited 1×
“in individuals with precocious puberty (10, 11).”
Thelarche, pubarche, and menarche attainment in children with normal and elevated body mass index
Rosenfield, R. L., Lipton, R. B., & Drum, M. L. (2009) · PEDIATRICS · doi:10.1542/peds.2008-0146 · Cited by 499
Herman-Giddens, M. E., Steffes, J., Harris, D., Slora, E., Hussey, M., Dowshen, S. A., Wasserman, R., Serwint, J. R., Smitherman, L., & Reiter, E. O. (2012) · PEDIATRICS · doi:10.1542/peds.2011-3291 · Cited by 392
Sørensen, K., Mouritsen, A., Aksglaede, L., Hagen, C. P., Mogensen, S. S., & Juul, A. (2012) · Hormone Research in Paediatrics · doi:10.1159/000336325 · Cited by 386
Cited by
Items 101–200 of 260
Karavani, G., Chill, H. H., Schachter‐Safrai, N., Lomnitz, G., Gillis, D., & Bauman, D. (2021) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-021-00129-4 · Cited by 12
“3 U/L using ultra-sensitive assays [5].”
LeBreton, L., Allain, E. P., Parscan, R. C., Crapoulet, N., Almaghraby, A., & Amor, M. B. (2022) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.63096 · Cited by 11
“Approximately 90% of females with CPP have no identifiable cause (idiopathic), but genetic factors are thought to have a significant control on the timing of puberty (Fuqua, 2013; Palmert & Boepple, 2001).”
BackgroundEtiology and therapeutic outcomes of children with gonadotropin-independent precocious puberty
Kang, E., Cho, J. H., Choi, J., & Yoo, H. (2016) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2016.21.3.136 · Cited by 12
Childhood tolerance of severe influenza: a mortality analysis in mice
Suber, F., & Kobzik, L. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00364.2017 · Cited by 11
Benefits of aerobic training in girls with precocious puberty: involvement of CRP and cortisol
Heidarianpour, A., Shokri, E., Baghian, T., & Shokri, B. (2019) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2018-0484 · Cited by 12
Yoo, J. W., Song, C. W., & Lim, H. H. (2016) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2016.21.4.199 · Cited by 10
“The major findings of this study were: (1) changes in leptin levels in girls with CPP during treatment with GnRHa were associated only with changes in BMI, and not with puberty states and suppression of the hypothalamus-pituitar ygonad (H-P-G) axis; and (2) glucose homeostasis and serum adiponectin levels in girls wit…”
ResultHeidarianpour, A., Shokri, E., Sadeghian, E., Cheraghi, F., & Razavi, Z. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1241744 · Cited by 9
“Overall, it can be concluded that overweight and obese children with CPP who participated in the training program experienced a decrease in cortisol, anxiety, depression, and anger compared with the Con.”
BackgroundInfluentialDifference in precocious puberty between pre–COVID-19 and COVID-19 periods: a meta-analysis
Nguyen, N. N., Dang, T. D., Hieu, T. H., Nam, A., & Cheng, Y.-C. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae295 · Cited by 11
Precocious puberty: An experience from a major teaching hospital in Central Saudi Arabia.
Osman, H. A., Al-Jurayyan, N. A. M., Babiker, A. M. I., Alotaibi, H., AlKhalifah, R. A. H., Al-Issa, S. D. A., & Mohamed, S. (2017) · Europe PMC (PubMed Central) · Cited by 13
The Use of Gonadotropin-Releasing Hormone Analogs beyond Precocious Puberty
Eugster, E. A. (2015) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2015.05.031 · Cited by 10
“Since the advent of these drugs as first-line therapy for CPP, a plethora of GnRHas have been developed that use different routes of administration, have unique delivery systems, and have varying durations of action.(7,8) Given the undisputed success of GnRHas in the setting of CPP, it is not surprising that there has…”
BackgroundHepatoblastoma presenting as precocious puberty: a case report
Marino, S., Caruso, M. M., Magro, G. G., D’Amico, S., Spina, M. L., Moscheo, C., Russo, G. M., & Cataldo, A. D. (2014) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2014-0167 · Cited by 9
Central Precocious Puberty – Management and Long-term Outcomes
Léger, J., Université Paris Diderot, S. P. C., & Institut National de la Santé et de la Recherche Médicale (Inserm), U. 1. (2015) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2015.11.01.45 · Cited by 12
“Central magnetic resonance imaging focusing on the hypothalamic region is required in most cases of CPP.(1,12)”
InfluentialAgrawal, M., Samala, R., Doddamani, R. S., Goyal, A., Tripathi, M., & Chandra, P. S. (2021) · Neurosurgical Review · doi:10.1007/s10143-021-01512-6 · Cited by 8
“Apart from being effective in arresting pubertal progression, these agents have also been demonstrated to improve adult height outcomes, especially when started early, at age <6 years [13, 21, 26, 28].”
BackgroundInfluentialPrecocious Puberty, GnRH Stimulation Test and Monitoring GnRH Analog Therapy
Menon, P. S. N. (2015) · The Indian Journal of Pediatrics · doi:10.1007/s12098-015-1903-3 · Cited by 8
“Girls with onset of progressive central precocious puberty (CPP) before 6 y of age and boys before 9 y of age benefit most in terms of height with GnRH analog (GnRHa) therapy [1].”
BackgroundInfluentialTiming of onset of menses after GnRH agonist treatment for central precocious puberty
Klein, K. O., Trujillo, M. V., Dragnic, S., Komen, S. V., Li, M., & Lee, P. A. (2024) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2023-0543 · Cited by 7
Height benefit of GnRH agonists after age 8 in a Portuguese cohort of central precocious puberty
Castro, C., Espada, F., Leite, A. L., Antunes, A. L. M. D. S., Robalo, B., Amaral, D., Galo, E., Castro, S., Ferreira, S., & Limbert, C. (2023) · Clinical Endocrinology · doi:10.1111/cen.14884 · Cited by 7
“By suppressing premature bone maturation and pubertal development, GnRHa preserves the adult height potential and allows synchronization of the pubertal stage with peers, preventing psychosocial and behavioural issues related to early puberty and menarche.(3,7,9,10) Several historical studies have reported increased f…”
BackgroundBreast Ultrasonography: Findings in Pediatric Patients
Harth, S., Behrens, C., Roller, F. C., Alzen, G., & Krombach, G. A. (2016) · Ultraschall in der Medizin - European Journal of Ultrasound · doi:10.1055/s-0041-108010 · Cited by 7
“The conventional accepted definition of premature thelarche is the onset of breast development before the age of 8 years [14].”
BackgroundKim, K. R., Trinh, T. A., Baek, J. Y., Lee, D. Y., Lim, S. H., Kim, J., Lee, W.-Y., Kim, C.-E., Kang, K. S., & Lee, H. L. (2021) · Plants · doi:10.3390/plants11010023 · Cited by 7
“The long-term continuous stimulation of the anterior pituitary downregulates its responsiveness, which suppresses the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [8,9].”
BackgroundInfluentialZhang, Y., Sun, N., Zhang, M., Ding, Q., Wang, Q., Liang, Y., He, H., Yang, Y., & Guo, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.852550 · Cited by 9
“Other side effects include headache, hot flashes, decreased bone density, and vaginal bleeding (Fuqua, 2013).”
BackgroundLerman, L., Yackobovitch‐Gavan, M., Phillip, M., & Shalitin, S. (2023) · Pediatric Research · doi:10.1038/s41390-023-02879-6 · Cited by 7
Vurallı, D., Alikaşifoğlu, A., İyigün, İ., Emet, D. C., Özön, A., Gonc, N. E., & Kandemir, N. (2019) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2019.2019.0060 · Cited by 7
“While short-acting nasal and daily injectable forms of GnRHa have been used previously, currently long-acting (monthly) or very-long-acting (three monthly) depot formulations or yearly implants that facilitate adherence to treatment are more commonly preferred (1,3,5).”
BackgroundAkhtar, R. W., Shah, S. A. H., & Qureshi, I. (2017) · Theriogenology · doi:10.1016/j.theriogenology.2017.07.027 · Cited by 7
Paparella, R., Bei, A., Brilli, L., Maglione, V., Tarani, F., Niceta, M., Pucarelli, I., & Tarani, L. (2025) · Endocrines · doi:10.3390/endocrines6020029 · Cited by 9
Klein, K. O., Miller, B. S., & Mauras, N. (2024) · Hormone Research in Paediatrics · doi:10.1159/000539110 · Cited by 6
Correlation of pelvic ultrasonography with pubertal development in girls
Bertoncello, F. Z., Beust, M. F., Tagliari, C. M., Herter, L. D., & Kopacek, C. (2024) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.61622/rbgo/2024ao05 · Cited by 6
Almutlaq, N., O’Neil, J., & Fuqua, J. S. (2020) · Journal of Pediatric Rehabilitation Medicine · doi:10.3233/prm-200728 · Cited by 6
“There were no side effects noticed during this treatment [19].”
BackgroundSelf-citationChen, Z., Si, L., Zhang, X., Wei, C., Shu, W., Meng, W., Cheng, L., Chen, Z., Qiao, Y., & Yang, S. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114783 · Cited by 6
Presentation of central precocious puberty in two patients with Tay-Sachs disease
Acar, S., Arslan, N., Paketçi, A., Okur, T. D., Demir, K., Böber, E., & Abacı, A. (2018) · HORMONES · doi:10.1007/s42000-018-0043-3 · Cited by 6
Lee, J., Kwak, M. J., & Ju, H. O. (2019) · Journal of Pediatric Nursing · doi:10.1016/j.pedn.2019.01.012 · Cited by 7
Jang, H. J., Kwak, M. J., Kim, Y. M., Choi, S., Park, K. H., Yoo, H. W., Park, S. J., Jo, Y. H., & Jo, H. Y. (2023) · Journal of Yeungnam Medical Science · doi:10.12701/jyms.2023.00801 · Cited by 5
Bird's-Eye View of GnRH Analog use in a Pediatric Endocrinology Referral Center
Watson, S. E., Greene, A., Lewis, K., & Eugster, E. A. (2015) · Endocrine Practice · doi:10.4158/ep14412.or · Cited by 5
“Gonadotropin-releasing hormone analogs (GnRHa) are well established as the treatment of choice for central precocious puberty (CPP) (1).”
Precocious pubertal development: a challenge for pediatric endocrinologists
Iughetti, L., & Lucaccioni, L. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.960846 · Cited by 5
“Early sexual development in girls may lead to unwanted sexual advances, which may be particularly challenging to manage in those with coexisting learning difficulties [18,19].”
BackgroundLong-Term Treatment With Letrozole in a Boy With Familial Male-Limited Precocious Puberty
Yuan, X., Chen, R., Zhang, Y., Yang, X., & Lin, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.906852 · Cited by 6
Shokri, B., Heidarianpour, A., & Shokri, E. (2023) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000003138 · Cited by 6
Relevance of augmented kisspeptin signaling through H364 KISS1R in central precocious puberty
Banerjee, A. A., Bhanarkar, S. R., Keshwani, R., Pande, S. S., Modi, D. N., Mehta, A. R., Bombe, S., Pathak, B. R., Joshi, B. N., Tandon, D., et al. (2023) · Gene · doi:10.1016/j.gene.2023.148016 · Cited by 5
Treatment of Central Precocious Puberty with a Focus on Girls
Krishna, K. B., Klein, K. O., & Eugster, E. A. (2024) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.01.004 · Cited by 8
Precocious pseudopuberty, a paraneoplastic manifestation: a report of 2 cases
Gattuso, G., Casanova, M., Biassoni, V., Terenziani, M., Schiavello, E., Sironi, G., Collini, P., Pallotti, F., Morosi, C., & Massimino, M. (2020) · Tumori Journal · doi:10.1177/0300891620925532 · Cited by 5
Gohil, A., & Eugster, E. A. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.12.030 · Cited by 5
Najafi, R., Heidarianpour, A., Shokri, E., & Shokri, B. (2023) · Scientific Reports · doi:10.1038/s41598-023-42828-1 · Cited by 6
“Provoca-tive test with GnRH agonist while precise cutoffs are difficult to establish, a peak stimulated LH of > ∼ 8 mIU/ mL after GnRH and > ∼ 5 IU/L after GnRHa are considered indicative of CPP 5 .”
BackgroundInfluentialDiagnosis, Treatment, and Outcomes of Males with Central Precocious Puberty
Robilliard, R., Lee, P. A., & Topor, L. S. (2024) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.01.005 · Cited by 4
Treatment of Central Precocious Puberty Using Gonadotropin-releasing Hormone Agonists
Cafasso, M., Elder, D. A., Blum, S., Weis, T., Hornung, L. N., Khoury, J. C., Stenger, P. J., & Rose, S. R. (2015) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2015.05.001 · Cited by 4
Gonadotropin-Dependent Precocious Puberty: Single-Center Experience From Western India
Phadte, A., Sarathi, V., Budyal, S. R., Lila, A. R., Memon, S. S., Karlekar, M. P., Patil, V. A., Shah, N. S., & Bandgar, T. (2023) · Indian Pediatrics · doi:10.1007/s13312-023-2909-y · Cited by 4
“Most patients had regression/stabilization of puberty despite the majority receiving three-monthly preparations, similar to the literature [18].”
GnRH-dependent precocious puberty manifested at the age of 14 months in a girl with 47,XXX karyotype
Skordis, N., Ferrari, E., Antoniadou, A., Phylactou, L. A., Fanis, P., & Neocleous, V. (2017) · HORMONES · doi:10.14310/horm.2002.1740 · Cited by 4
Liu, L., Wan, N., & Sun, H. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/8091846 · Cited by 4
“If the patients with rapid onset and progress are not intervened in time, peripheral precocious puberty may turn to central precocious puberty [4].”
BackgroundGaikwad, P. M., Goswami, S., Sengupta, N., Baidya, A., & Das, N. (2022) · Cureus · doi:10.7759/cureus.22676 · Cited by 4
Hypothalamic hamartoma: a cause of precocious puberty
Castro, C., Morais, J. M., Correia, A. L., & Espada, F. (2023) · BMJ Case Reports · doi:10.1136/bcr-2022-254429 · Cited by 4
Xu, L., Li, P., & Yuan, D. (2023) · BMC Pediatrics · doi:10.1186/s12887-023-04447-7 · Cited by 4
“The development of secondary sex characteristics before the age of 8 years in girls or before the age of 9 years in boys is considered precocious puberty, which is relatively common in girls [1–3].”
BackgroundSendler, D. J., & Szewczyk, A. (2019) · Pediatric Medicine · doi:10.21037/pm.2019.04.05 · Cited by 3
Association of Early Pubertal Onset in Female Rats With Inhalation of Lavender Oil
Kim, Y., & Lim, H. H. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e9 · Cited by 3
COVID‐19 and early puberty—An unintended consequence of COVID‐19 lockdown?
Sheikh, A., Owais, R., Ali, E., & Shaikh, A. J. (2023) · Developmental Psychobiology · doi:10.1002/dev.22384 · Cited by 3
Use of the Subcutaneous Triptorelin Stimulation Test for Diagnosis of Central Precocious Puberty
Ahn, J., Lee, Y., Gim, S., & Jeong, H. R. (2023) · Children · doi:10.3390/children10111830 · Cited by 3
“In the Republic of Korea, it is defined as a peak LH level of >5 IU/L in either the gonadorelin or triptorelin stimulation test [18,19].”
BackgroundDiagnostic value of adenohypophyseal MRI features in female children with precocious puberty
Liu, D., Liu, W. V., Zhang, L., Qin, Y., Li, Y., Ding, G., Zhou, Y., Xie, Y., Chen, P., & Zhu, W. (2023) · Clinical Radiology · doi:10.1016/j.crad.2023.11.020 · Cited by 3
Cheng, H., & Wan, X. (2025) · Natural Product Communications · doi:10.1177/1934578x251323772 · Cited by 3
Wu, Y., & Zhao, W. (2025) · Growth Factors · doi:10.1080/08977194.2025.2521071 · Cited by 3
“Further, it is crucial to distinguish CPP from isolated PT as the clinical course, and treatment strategies differ for these two conditions (Chen and Eugster 2015; Alghamdi 2023; Fuqua 2013).”
Martínez, M., Pereyra, S., Ventura, D., & Cabello, E. (2020) · ACTA MEDICA PERUANA · doi:10.35663/amp.2020.371.966 · Cited by 3
Maqdasy, S., Barres, B., Salaün, G., Batisse‐Lignier, M., Pebrel‐Richard, C., Kwok, K. H. M., Labbé, A., Touraine, P. A., Brugnon, F., & Tauveron, I. (2020) · Basic and Clinical Andrology · doi:10.1186/s12610-020-00117-1 · Cited by 4
Kılınç, S. (2019) · Haydarpasa Numune Training and Research Hospital Medical Journal · doi:10.14744/hnhj.2019.53765 · Cited by 3
Self-puberty staging in endocrine encounters during the COVID pandemic
Ebo, C., McCray, J., Bowers, K. A., Rose, S. R., & Jones, N. Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1487329 · Cited by 3
Lazar, L., Oron, T., Yackobovitch‐Gavan, M., Tenenbaum, A., Phillip, M., Meyerovitch, J., & de Vries, L. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf427 · Cited by 3
Gohil, A., & Eugster, E. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-56963-7.00004-1 · Cited by 3
Khokhar, A., Ravichandran, Y., Stefanov, D. G., & Perez-Colon, S. (2017) · International Journal of Adolescent Medicine and Health · doi:10.1515/ijamh-2016-0122 · Cited by 4
“More recent data suggest earlier onset of puberty in the US children [9], though in clinical practice the traditional cutoffs are still accepted by most pediatricians and endocrinologists [10].”
Effect of kisspeptin injection on reproductive performance of Ossimi rams in subtropics
Abdel‐Ghani, M. A., & Mahmoud, G. B. (2019) · Small Ruminant Research · doi:10.1016/j.smallrumres.2019.09.004 · Cited by 3
Villasmil, M. G. P., Kim, C., Sato, M., & Kanner, L. A. (2022) · AACE Clinical Case Reports · doi:10.1016/j.aace.2022.04.005 · Cited by 3
Congenital adrenal hyperplasia complicated by gonadotropin-dependent precocious puberty
Alam, A., Agrawal, N. K., & Singh, S. K. (2024) · BMJ Case Reports · doi:10.1136/bcr-2023-257579 · Cited by 2
Precocious Puberty Therapeutic Management: GnRH Analogs Treatment
Bouvattier, C. M. (2015) · Springer eBooks · doi:10.1007/978-2-8178-0543-6_7 · Cited by 2
Management of Peripheral Precocious Puberty in Girls
Sultan, C., Gaspari, L., Kalfa, N., & Paris, F. (2017) · ISGE series · doi:10.1007/978-3-319-41433-1_4 · Cited by 2
Fu, Y., Zhang, W., Bo, T., Yang, B., Yang, D., Xie, X., Liu, P., Zhu, Y., Zhou, L., Chen, T., et al. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00784 · Cited by 2
Central precocious puberty: assessment, diagnosis and decisions about treatment
Mason, L., & Daskas, N. (2024) · Nursing Children and Young People · doi:10.7748/ncyp.2024.e1492 · Cited by 3
Haddad, N. G., & Eugster, E. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00121-9 · Cited by 3
Pubertad precoz: no solo una cuestión de edad
Almache, O. N. (2015) · Anales de la Facultad de Medicina · doi:10.15381/anales.v76i3.11239 · Cited by 5
“tratamiento con GnRH en niñas con pubertad temprana (62, 63).”
BackgroundCentral Precocious Puberty: From Diagnosis to Treatment
Léger, J., & Carel, J. (2017) · ISGE series · doi:10.1007/978-3-319-41433-1_3 · Cited by 2
Pubertal assessment: targeted educational intervention for pediatric trainees
Khokhar, A., Nagarajan, S., Ravichandran, Y., & Perez-Colon, S. (2017) · International Journal of Adolescent Medicine and Health · doi:10.1515/ijamh-2017-0064 · Cited by 2
“With the rising incidence of precocious puberty among children in the United States (US) [1], it is imperative for pediatricians to have a working knowledge of pubertal assessment and sexual maturity rating (SMR)/Tanner stages [2], [3].”
BackgroundLéger, J., & Carel, J. (2016) · Springer eBooks · doi:10.1007/978-3-319-32122-6_10 · Cited by 4
Kalynovskyi, V., Pustovalov, A. S., Grodzyuk, G. Y., Andriushyna, N. S., & Dzerzhynsky, M. E. (2016) · Neurophysiology · doi:10.1007/s11062-016-9597-3 · Cited by 2
Furtado, C. L. M., Iannetta, R., Ferriani, R. A., Silva, A. C. J. D. S. R. E., Martinelli, C. E., Calado, R. T., & dos Reis, R. M. (2020) · Gynecological Endocrinology · doi:10.1080/09513590.2020.1770212 · Cited by 2
Misra, M., & Radovick, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-73782-9_26 · Cited by 2
Precocious puberty in a 24 month old Nigerian girl: case report
Oluwayemi, I. O., Afolabi, A. A., Adeniji, E. O., & Ayeni, T. O. (2020) · Nigerian Journal of Paediatrics · doi:10.4314/njp.v47i4.10 · Cited by 1
Analogues of hypothalamic/pituitary/gonadal hormone regulators for the management pubertal disorders
Millar, R. P., & Newton, C. L. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.09.007 · Cited by 2
Hosseini, Z. S., Arani, K. S., Moraveji, A., & Talari, H. R. (2022) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2021.109267 · Cited by 1
“Precocious puberty can cause secondary sexual characteristics, aggressive behaviour, and, most importantly, it can limit the final adult height [2-5].”
BackgroundAssessing adolescent gynecomastia: The role of shear wave ultrasound elastography
Parlak, A. E., Gok, O. V., Toslak, İ. E., Baran, R. T., & Parlak, M. (2024) · Journal of Clinical Ultrasound · doi:10.1002/jcu.23831 · Cited by 1
Juxtaposition of Bone Age and Sexual Maturity Rating of the Taiwanese Population
Lu, W., Wang, C., Lin, Y.-C., & Tsai, F. (2024) · Biomedicine · doi:10.37796/2211-8039.1466 · Cited by 1
“While Marshall and Tanner associated SMR with the CA at which each stage was reached, increasing evidence suggests variability in the CA at which SMR is reached between individuals of different ethnicities [5].”
Wang, M., Zhao, R. Y., & Wang, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1703077 · Cited by 1
“( Fuqua, 2013).”
Chen, Z., Li, W., Wang, J., Dong, Z., Li, C., Wang, W., Hu, R., Ma, X., Xiao, Y., & Lü, W. (2025) · International Journal of Endocrinology · doi:10.1155/ije/5609749 · Cited by 1
“Children with very early onset CPP ( 6 years old) mainly come to a satisfactory FH, which may reach the TH range or signifcantly exceed PAH at the beginning of therapy [10, 26–28].”
Postinjection Muscle Fibrosis from Lupron
Everest, E., Tsilianidis, L. A., Raissouni, N., Ballock, R. T., Blatnik, T., Haider, A., Rogers, D. G., & Schweiger, B. M. (2015) · Case Reports in Pediatrics · doi:10.1155/2015/938264 · Cited by 1
“Males are more likely to have pathological causes for central precocious puberty [1].”
BackgroundStyne, D. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-18371-8_9 · Cited by 1
Psödotumör Serebri; Tek Merkez Deneyimi
Özkale, Y. (2018) · Turkish Journal of Pediatric Disease · doi:10.12956/tjpd.2018.364 · Cited by 1
“Çalışma retrospektif olduğundan, püberteyi tanımlamak için yaş ve cinsiyete özgü kriterlere tüm olgularda ulaşılamadığından 11 yaşından küçük hastalar prepübertal, üstü ise pübertal olarak kabul edildi (10).”
Diagnosis of Precocious Puberty in Girls
Gaudino, R., Calcaterra, V., Farello, G., Gasparri, M., Monti, C. M., Bozzola, E., Villani, A., & Bozzola, M. (2020) · International Journal of Pediatrics and Child Health · doi:10.12974/2311-8687.2020.08.1 · Cited by 1
“Although bone age is typically advanced, this is certainly not exclusive to CPP and may be seen to a milder degree in numerous other conditions [16].”
BackgroundCare of the Child with a Pediatric Endocrine Disorder
Crespi, R., Pughe, L., & Dowd, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-90642-9_11 · Cited by 1
Menstrual Problems and Vaginal Bleeding
Francis, J. C., & Menon, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-76174-1.00025-0 · Cited by 1
Kobra, S. A. (2024) · Open Access Journal of Endocrinology · doi:10.23880/oaje-16000190 · Cited by 1
Bercaw‐Pratt, J. L. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0912-4_7 · Cited by 1
“While patients are treated for the cause of the peripheral precocious puberty, they must also be monitored for signs of continued development which may signify the onset of central precocious puberty [ 1 ].”
BackgroundInfluentialGynecologic Issues in the Pediatric and Adolescent Patient with Cancer
Trotman, G. E., & Hoefgen, H. R. (2016) · Current Treatment Options in Pediatrics · doi:10.1007/s40746-016-0059-3 · Cited by 2
Midterm and Long-Term Impacts of GnRH Agonists Treatments
Chao, C., & Christin‐Maître, S. (2015) · Springer eBooks · doi:10.1007/978-2-8178-0543-6_8 · Cited by 1
Karamizadeh, Z., Rasekhi, A. R., Kashef, S., Saki, F., & Ashkani‐Esfahani, S. (2017) · Iranian Journal of Pediatrics · doi:10.5812/ijp.7495 · Cited by 1
“The occurrence of these side effects is assumed to be directly related to the dose of the drug, thus, every effort should be made to reduce the dose with noticeable influence on the final outcome (5).”
BackgroundResultEndocrine Deficits in Patients with Human Craniopharyngioma
Gan, H., Spoudeas, H. A., & Dattani, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-51890-9_5 · Cited by 1
Menstrual Problems and Vaginal Bleeding
Francis, J. C., & Menon, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-39956-2.00022-4 · Cited by 2
Duration of Pubertal Suppression and Initiation of Gender-Affirming Hormone Treatment in Youth
Kinnear, H. M., & Shumer, D. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-56963-7.00010-7 · Cited by 1
Evaluation of Characteristics of the Dental Maturity in Girls with Precocious Puberty
Kim, C., Kang, C., Kim, I.-H., Song, J. S., & Kim, S. (2020) · THE JOURNAL OF THE KOREAN ACADEMY OF PEDTATRIC DENTISTRY · doi:10.5933/jkapd.2020.47.3.312 · Cited by 1
“성조숙증의 발병률은 남아보다 여아에서 10 - 15배 더 높으며, 여아의 연간 발병률은 8년 동안 100,000명당 15 - 29명으로 보 고된 바 있다[2].”
Laparoscopy decision for precocious pseudopuberty of ovarian origin
Fu, J. Y., Lu, Y., & Huang, W. (2019) · Clinical and Experimental Obstetrics & Gynecology · doi:10.12891/ceog4715.2019 · Cited by 1
Endocrine disorders in infants, children, and adolescents
Shi, M., & PAGE, L. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818872-9.00050-9 · Cited by 2
Metadata
- Authors
- Fuqua, J. S.
- Affiliations
- Indiana University Indianapolis (US)
- Corresponding author
- Fuqua, John S.
- ORCID
- Fuqua, John S.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-06-01
- Volume
- 98
- Issue
- 6
- Pages
- 2198-2207
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2170468182
- Cited by
- 260
- References
- 61
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 20 · 2023: 27 · 2022: 17 · 2021: 23 · 2020: 21 · 2019: 23 · 2018: 12 · 2017: 22 · 2016: 13 · 2015: 31 · 2014: 20 · 2013: 4
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- precocious puberty, central precocious puberty, GnRH analogues, kisspeptin, neurokinin B, dynorphin, leuprolide, familial male-limited precocious puberty, McCune-Albright syndrome, polycystic ovary syndrome, skeletal maturation, psychological outcomes, treatment outcomes
- MeSH terms
- Delayed-Action Preparations, Drug Implants, Female, Humans, Gonadotropin-Releasing Hormone, Male, Puberty, Puberty, Precocious, Leuprolide, Treatment Outcome, Kisspeptins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.